Exicure Inc XCUR

$1.05 -0.08 (-7.08%)

Valuation

Market cap
6,873,000
Revenue TTM
$0
Net income TTM
$-4,950,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
61,200
Avg volume
47,222
Day's range
$1.04 – $1.14
Shares out
6,546,000
Stochastic %K
24%
Beta
3.64
Analysts
Strong Buy
Price target
$2.00

Price

Company profile

Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

Industry
Biotechnology
Sector
Healthcare
Phone
847 673 1700
Website
https://www.exicuretx.com
Address
400 Seaport Court, Suite 102, Redwood City, United States

Latest news

Stocktwits

KingsFourVerseTwentyNine Oct 25, 5:01 AM
$XCUR 🚨 GLOBAL DD — PART 58 🌎🚀 👀 FOLLOW THE INDEX ELIGIBILITY CATALYST! 🔥 NASDAQ | MICROCAP | QUANT FUNDS | GLOBAL EQUITIES 🔹 Institutional portfolios often operate under minimum market capitalization, liquidity and listing requirements. 🔹 Smaller biotechnology companies may fall outside these investment mandates. 🔹 A sustained improvement in XCUR's market value and trading liquidity could potentially expand its eligibility. 🔹 Quantitative strategies screen for market capitalization, free float, liquidity and index inclusion. 🔹 Meeting applicable index criteria could eventually introduce XCUR to additional passive and systematic investment strategies. 🔹 Greater institutional eligibility could broaden the shareholder base and support more efficient price discovery. $XCUR #Russell2000 #QuantFunds #GlobalMarkets #Biotech
0 replies
KingsFourVerseTwentyNine Oct 25, 4:59 AM
$XCUR 🚨 GLOBAL DD — PART 57 🌎🚀 👀 FOLLOW THE NON-DILUTIVE CAPITAL OPPORTUNITY! 🔥 NASDAQ | MICROCAP | BIOTECH | GLOBAL CAPITAL 🔹 Clinical-stage biotechnology companies often face significant financing requirements. 🔹 Traditional equity raises can dilute existing shareholders. 🔹 Strategic licensing partnerships may offer alternative funding through upfront payments and development support. 🔹 A partner-funded clinical program could potentially reduce XCUR's direct capital requirements. 🔹 Institutional investors evaluate cash runway, financing structure and dilution alongside scientific progress. 🔹 A confirmed non-dilutive agreement could strengthen the investment thesis without requiring an equivalent issuance of new shares. 🚀 **GLOBAL CATALYST WATCH:** Non-Dilutive Funding | Strategic Partnerships | Cash Runway | Licensing Revenue | Capital Efficiency | Shareholder Value $XCUR #Biotech #HedgeFunds #GlobalMarkets #CapitalMarkets
0 replies
KingsFourVerseTwentyNine Oct 25, 4:58 AM
$XCUR 🚨 GLOBAL DD — PART 56 🌎🚀 👀 FOLLOW THE ANALYST COVERAGE GAP! 🔥 NASDAQ | MICROCAP | BIOTECH | GLOBAL EQUITIES 🔹 Small biotechnology companies often receive limited institutional research coverage. 🔹 Limited coverage can create information gaps between clinical developments and market valuations. 🔹 GPC-100's clinical history provides material for independent scientific and financial analysis. 🔹 New analyst coverage could introduce XCUR to investors who previously overlooked the company. 🔹 Published research could help institutions evaluate clinical probabilities, licensing economics and potential commercial markets. 🔹 A verified strategic catalyst combined with broader research coverage could support more efficient price discovery. 🚀 **GLOBAL CATALYST WATCH:** Analyst Initiation | Research Coverage | Institutional Discovery | rNPV | Market Inefficiency | Valuation Re-Rating $XCUR #EquityResearch #HedgeFunds #GlobalMarkets #Biotech
0 replies
Bolo44 Oct 24, 1:45 AM
$XCUR total scam
0 replies
Bolo44 Oct 23, 9:14 PM
$XCUR unfortunately they lost government contracts
0 replies
Nimrod44 Oct 23, 6:37 PM
$IMNN $XCUR
0 replies
KingsFourVerseTwentyNine Oct 23, 3:19 PM
$XCUR GLOBAL DD — PART 55 🌎 GLOBAL PRICE DISCOVERY! 🔥 NASDAQ | GLOBAL EQUITIES | MICROCAP | CROSS-MARKET 🔹 U.S.-listed biotech companies can attract investors across North America, Europe and Asia. 🔹 International investors evaluate clinical assets using different market assumptions, currencies and regional opportunities. 🔹 Cross-border research coverage could expand awareness of GPC-100 and XCUR's licensed rights. 🔹 A verified overseas partnership could introduce new investors to the company's commercial potential. 🔹 Global equity screens track foreign trading interest, liquidity, corporate announcements and valuation discrepancies. 🔹 Broader investor participation could improve price discovery if supported by genuine demand. **GLOBAL CATALYST WATCH:** International Capital | Cross-Border Investment | Global Licensing | Foreign Institutional Interest | Liquidity Expansion | Price Discovery $XCUR #GlobalMarkets #HedgeFunds #Biotech #InstitutionalInvesting
0 replies
KingsFourVerseTwentyNine Oct 23, 3:16 PM
🚨 $XCUR GLOBAL DD — PART 54 🚀 👀 FOLLOW THE RISK-ADJUSTED VALUATION! 🔥 NASDAQ | MICROCAP | BIOTECH | QUANT RESEARCH 🔹 Institutional biotech models often use risk-adjusted net present value (rNPV) to evaluate clinical-stage assets. 🔹 rNPV considers potential future revenue, development costs, timelines and probability of approval. 🔹 GPC-100's completed Phase II development provides clinical evidence for evaluating future scenarios. 🔹 A stronger probability-of-success estimate could materially influence theoretical asset valuations. 🔹 New clinical evidence or contractual economics could change assumptions used by biotech analysts. 🔹 A credible third-party valuation could give investors another benchmark for assessing XCUR's licensed rights. 🚀 **BULLISH CATALYST WATCH:** rNPV | Probability of Success | Clinical Valuation | Equity Research | Price Discovery | Fundamental Re-Rating $XCUR #QuantResearch #Biotech #HedgeFunds #ValueInvesting
0 replies